# Prelude Therapeutics Inc (PRLD)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/prelude-therapeutics-inc/ JSON: https://steadybase.io/company/prelude-therapeutics-inc.json Checked Nov 10, 2026. Latest filing read: Aug 11, 2026.

## Company

- Legal name: Prelude Therapeutics Inc
- Ticker: PRLD (Nasdaq)
- SEC CIK: 0001678660
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Wilmington, DE
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: preludetx.com
- LinkedIn: https://www.linkedin.com/company/prelude-therapeutics
- Next earnings date: Nov 11, 2026

## Key facts

- Revenue: $12.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.html
- Operating income: -$104.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.html
- Net income: -$99.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.html
- SG&A: $22.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.html
- Employees: 79 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Shares outstanding: 79,803,485 as of Aug 6, 2026 (10-Q filed Aug 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526343475/0001193125-26-343475-index.html
- Auditor: Ernst & Young LLP, Philadelphia, Pennsylvania, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm

## Business

Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our clinical development capabilities, we have built an efficient, drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, or NCEs, that we advance into clinical trials.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $12.1M | -$104.6M | -$99.5M | $22.4M |
| Dec 31, 2024 | $7.0M | -$139.7M | -$127.2M | $28.7M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/prelude-therapeutics-inc.json

## Officers and directors

- Krishna Vaddi, Chief Executive Officer and Director. LinkedIn: https://linkedin.com/in/kris-vaddi-ph-d-7b41867. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Bryant Lim, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/bryantlim. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Bryant David Lim, CLO, CFO, Corp Sec.. Source: Form 4 filed Feb 5, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000175288826000002/0001752888-26-000002-index.htm
- Jane Huang, President, CMO. Source: Form 4 filed Oct 7, 2025, https://www.sec.gov/Archives/edgar/data/1678660/000168391325000004/0001683913-25-000004-index.htm
- Charles Q. Morris, Chief Medical Officer. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000148996626000004/0001489966-26-000004-index.htm
- Sean P. Brusky, Chief Business Officer. Source: Form 3 filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000092963826001070/0000929638-26-001070-index.htm
- Andrew Combs, Chief Chemistry Officer. LinkedIn: https://linkedin.com/in/andrew-combs-4514413. Source: Form 4 filed Feb 5, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000182500526000002/0001825005-26-000002-index.htm
- Peggy Scherle, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/peggy-scherle-b3663324. Source: Form 4 filed Feb 5, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000182463226000002/0001824632-26-000002-index.htm
- Paul A. Friedman, Chairman and Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- David P. Bonita, M.D., Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Katina Dorton, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Martin Babler, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Paul Scherer, M.D., Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Victor Sandor, M.D.C.M., Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- Andrew P. Combs, Named in proxy. Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm
- David P. Bonita, Board member (per proxy). Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm
- Paul Scherer, Board member (per proxy). Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm
- Peggy A. Scherle, Named in proxy. Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm
- Victor Sandor, Board member (per proxy). Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm

## Recent 8-K events

- Sep 10, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm
- Aug 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm
- Jun 10, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/prld-20260609.htm
- May 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-20260512.htm
- Apr 21, 2026: Item 1.01, Entry into a material definitive agreement; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526164510/d131537d8k.htm
- Apr 20, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/d135229d8k.htm
- Apr 15, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526155978/prld-20260415.htm
- Mar 12, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526104204/d916869d8k.htm
- Mar 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/prld-20260310.htm
- Feb 3, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1678660/000119312526034564/prld-20260129.htm

## Insider trades (Form 4)

- Apr 21, 2026: David P. Bonita (Director) bought 2,815,315 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/1678660/000094787126000462/0000947871-26-000462-index.htm
- Apr 21, 2026: Capital Llc Orbimed (Director) bought 2,815,315 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/1678660/000094787126000461/0000947871-26-000461-index.htm
- Apr 21, 2026: Advisors Llc Orbimed (Director) bought 2,815,315 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/1678660/000094787126000461/0000947871-26-000461-index.htm
- Apr 21, 2026: Capital GP VI LLC OrbiMed (Director) bought 2,815,315 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/1678660/000094787126000461/0000947871-26-000461-index.htm
- Apr 21, 2026: Genesis GP LLC OrbiMed (Director) bought 2,815,315 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/1678660/000094787126000461/0000947871-26-000461-index.htm

## Latest filings

- 8-K filed Sep 10, 2026: https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm
- 10-K filed Mar 10, 2026: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm
- 10-Q filed Aug 11, 2026: https://www.sec.gov/Archives/edgar/data/1678660/000119312526343475/prld-20260630.htm
- DEF 14A filed Apr 29, 2026: https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/